Sanofi has acquired Tidal Therapeutics in a deal worth $470 million, with Tidal eligible to receive $160 million as an upfront payment and an additional $310 million for a variety of milestone payments. Tidal is developing nanoparticles to deliver messenger RNA to immune cells for reprogramming against immune diseases and cancer.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.